We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Partners With Russia’s Gamaleya Research Institute for Combination COVID-19 Vaccine
AstraZeneca Partners With Russia’s Gamaleya Research Institute for Combination COVID-19 Vaccine
AstraZeneca (AZ) will soon launch a study evaluating a double-dose regimen of its COVID-19 candidate AZD1222 in combination with adenovirus-based vaccine Sputnik V, developed by Russia’s sovereign wealth fund and using the same technology as the AZ vaccine.